Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Indivior ( (INDV) ) just unveiled an announcement.
On March 12, 2026, Indivior Pharmaceuticals, Inc. announced it had priced an upsized private offering of $450 million aggregate principal amount of 0.625% convertible senior notes due 2031 to qualified institutional buyers under Rule 144A, with an option for initial purchasers to buy an additional $50 million. The notes, which are senior unsecured obligations, carry an initial conversion rate equivalent to a price of about $41.66 per share, a roughly 35% premium to the company’s March 12, 2026 Nasdaq closing price, and may be redeemed by Indivior from 2029 if share price conditions are met.
Indivior expects net proceeds of about $437.7 million, or up to $486.4 million if the option is fully exercised, and plans to use roughly $239 million plus $102 million of cash on hand to repay and terminate its existing term loan and revolving credit facilities, about $75 million to repurchase approximately 2.4 million shares in concurrent private transactions, and the remainder for general corporate purposes. The concurrent stock repurchases may have supported a higher trading price and, in turn, a higher initial conversion price for the notes, signaling a strategic balance-sheet refinancing that reduces reliance on traditional bank debt while returning capital to shareholders and potentially strengthening Indivior’s financial flexibility in its core opioid use disorder treatment market.
The most recent analyst rating on (INDV) stock is a Hold with a $33.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.
The score is driven primarily by improving forward outlook from the latest earnings call (strong EBITDA/margin and cash-flow guidance plus buyback), partially offset by weaker underlying financial quality (negative equity and inconsistent cash generation) and mixed technical momentum. Valuation appears reasonable but not a clear bargain at the current P/E.
To see Spark’s full report on INDV stock, click here.
More about Indivior
Indivior Pharmaceuticals, Inc. is a leader in long-acting injectable treatments for opioid use disorder, focusing on evidence-based therapies that address addiction as a chronic but treatable brain disease. With more than 25 years in addiction medicine, the company targets individuals living with opioid use disorder, working with public health stakeholders to support long-term recovery.
Building on its heritage in addiction science, Indivior develops products aimed at improving independence and dignity for patients while reinforcing its position in the opioid use disorder treatment market. The company emphasizes compassion, integrity, and scientific innovation as it collaborates with communities and public health champions to expand access to effective treatment options.
Average Trading Volume: 2,397,638
Technical Sentiment Signal: Buy
Current Market Cap: $3.86B
Find detailed analytics on INDV stock on TipRanks’ Stock Analysis page.